

Resource Summary Report

Generated by [NIF](#) on Sep 15, 2026

NCI-H2882

RRID:CVCL_5158

Type: Cell Line

Proper Citation

RRID:CVCL_5158

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5158

Proper Citation: RRID:CVCL_5158

Description: Cell line NCI-H2882 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung squamous cell carcinoma

Defining Citation: [PMID:10987304](#), [PMID:11030152](#), [PMID:11314036](#), [PMID:12759538](#), [PMID:20679594](#), [PMID:22961666](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:31068700](#), [PMID:31803961](#)

Comments: Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H2882

Synonyms: H2882, H-2882, NCIH2882

Cross References: BioSample:SAMN10989611, cancercellines:CVCL_5158, Cell_Model_Passport:SIDM01385, Cosmic:755471, Cosmic:903621, Cosmic:1146910, DepMap:ACH-000700, GEO:GSM108843, GEO:GSM108844, GEO:GSM253402, GEO:GSM434255, GEO:GSM794368, GEO:GSM817105, IGRhCellID:H2882GEO, Progenetix:CVCL_5158, Wikidata:Q54908011

ID: CVCL_5158

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260913T004955+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H2882.

No alerts have been found for NCI-H2882.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Martin-Vega A, et al. (2024) ASCL1 Restrains ERK1/2 to Promote Survival of a Subset of Neuroendocrine Lung Cancers. *Molecular cancer therapeutics*, 23(12), 1789.

Martin-Vega A, et al. (2023) ASCL1-ERK1/2 Axis: ASCL1 restrains ERK1/2 via the dual specificity phosphatase DUSP6 to promote survival of a subset of neuroendocrine lung cancers. *bioRxiv : the preprint server for biology*.

Bery N, et al. (2021) Protocol to select conformation-specific intracellular antibodies for targeted protein degradation in an engineered cell line. *STAR protocols*, 2(1), 100249.

Yenerall P, et al. (2020) RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. *Cell chemical biology*, 27(1), 105.

Bery N, et al. (2019) A Targeted Protein Degradation Cell-Based Screening for Nanobodies Selective toward the Cellular RHOB GTP-Bound Conformation. *Cell chemical biology*, 26(11), 1544.